Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022
May 12, 2022 at 12:35 pm EDT
Share
Nexien BioPharma, Inc. reported earnings results for the third quarter and nine months ended March 31, 2022. For the third quarter, the company reported net loss was USD 0.187451 million compared to net income of USD 0.211198 million a year ago. Basic loss per share from continuing operations was USD 0.003.
For the nine months, net loss was USD 0.529356 million compared to USD 1.68 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago.
Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.
NEXIEN BIOPHARMA, INC. 
